Sandoz enters agreement to develop non-opioid pain relief
Sandoz has entered into a development and commercialisation agreement with pharmaceutical company Durect to develop the drug Posimir (Saber-bupivacaine).
Posimir is a non-opioid analgesic which provides up to three days of pain relief after surgery.
According to a statement released on Monday, May 8, Sandoz will make an upfront payment to Durect of $20 million, with the potential for an additional $43 million in development and regulatory milestones.
Durect will also receive up to a further $230 million in sales-based milestones.
Under the agreement, Durect will remain responsible for the completion of the clinical trial for Posimir.
James Brown, president of Durect, said: “We believe that Posimir has the potential to become a cornerstone of multi-modal post-operative pain management.”
He added: “As a non-opioid local analgesic, we believe Posimir may be an important contributor to the ongoing efforts to reduce the use of opioid-based medications following surgery.”
The transaction is expected to close during the second quarter of 2017.
Join us for a FREE webinar - The Halo effect: walking the wilfulness tightrope - on May 16
Did you enjoy reading this story? Sign up to our free newsletter and get stories like this sent straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk